Supira Medical

The company is developing a low-profile, high continuous flow percutaneous ventricular assist device (pVAD) for high risk PCI and cardiogenic shock. pVADs provide temporary mechanical support by assisting the heart’s native pumping action.

Loma Linda University Medical Center is the first healthcare provider in Southern California to test Supira Medical’s investigational **pulsatile ventricular assist device (pVAD)** in the **SUPPORT II clinical trial**. The device is being evaluated as part of a broader study assessing its role in advanced heart failure treatment. Supira Medical announced the milestone on LinkedIn, emphasizing the center’s participation in this phase of research.

Sep 2026Supira MedicalNews article

Prisma Health Heart and Vascular Institute enrolls the first patient in the Southeastern U.S. in Supira Medical’s SUPPORT II pivotal study. The milestone marks the institute’s participation in evaluating Supira Medical’s cardiovascular technology. The study aims to advance treatment options for heart and vascular conditions.

Aug 2026Supira MedicalNews article

UC Davis Health launches a clinical trial testing a novel device to enhance blood flow during high-risk coronary artery stenting procedures. The trial targets patients undergoing complex cardiovascular interventions. The institution joins the first sites in the U.S. to offer this experimental treatment.

Jun 2026newsNews article

Supira Medical raises **$120M in an oversubscribed Series E round**, led by Novo Holdings and Qatar Investment Authority, to advance its percutaneous ventricular assist device (pVAD) technology. The company also completes enrollment for its **SUPPORT I early feasibility study in the U.S.**, marking progress in clinical development. Strategic investors and existing backers participate in the funding, reinforcing confidence in Supira’s mission to transform heart-assist solutions.

Mar 2025Venture Capital Access OnlineNews article